Your search for ganciclovir returned 25 results

The FDA has notified healthcare professionals of new pediatric dosing recommendations for Valcyte (valganciclovir hydrochloride, from Roche) tablets and oral solution.

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Sirion Therapeutics has announced that Zirgan (ganciclovir ophthalmic gel) is now available for the treatment of acute herpetic keratitis (dendritic ulcers).

The FDA has approved Zirgan (ganciclovir ophthalmic gel, from Sirion Therapeutics) for the treatment of acute herpetic keratitis (dendritic ulcers).

The FDA has approved Valcyte (valganciclovir hydrochloride [prodrug of ganciclovir], from Roche) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.